Nitin Ohri
Advanced in Retroperitoneal Liposarcoma

Dr. Nitin Ohri

Radiation Oncology
Montefiore Einstein
Montefiore Einstein Comprehensive Cancer Center - Montefiore Medical Park
1625 Poplar Street, 
Bronx, NY 
Clinical Trials:Currently Recruiting for 5 Trials

Advanced in Retroperitoneal Liposarcoma
Montefiore Einstein
Montefiore Einstein Comprehensive Cancer Center - Montefiore Medical Park
1625 Poplar Street, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nitin Ohri, MD, MS, is Professor, Radiation Oncology at Montefiore Einstein. He is a radiation oncologist with a clinical focus on treating lung and gastrointestinal cancers.

Dr. Ohri is rated as an Advanced provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Nasopharyngeal Carcinoma, and Prostatectomy.

His clinical research consists of co-authoring 115 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Washington University School Of Medicine
Residency
Thomas Jefferson University Hospital
Specialties
Radiation Oncology
Licenses
Therapeutic Radiology in PA
Hospital Affiliations
Montefiore Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Archcare
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
The Wellness Plan Medical Centers
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Montefiore Einstein Comprehensive Cancer Center - Montefiore Medical Park
1625 Poplar Street, Bronx, NY 10461
Call: 718-405-8550
Other Locations
Brook Avenue At 951 Brook Avenue
951 Brook Avenue, Bronx, NY 10451
Call: 929-323-3737
Montefiore Einstein Radiation Oncology at North Highland
111 North Highland Avenue, Nyack, NY 10960
Call: 845-727-0828

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Memantine Hydrochloride
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Radiation, Drug
Study Drug: FLT3 Ligand Therapy (CDX-301)
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Combination product
Study Drugs: PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Study Phase: Phase 2
FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
Enrollment Status: Terminated
Publish Date: February 28, 2024
Intervention Type: Drug, Biological, Radiation
Study Drugs: FLT3 Ligand, Anti-CD40 antibody
Study Phase: Phase 1/Phase 2
PET-Adjusted IMRT for NSCLC Trial (PAINT)
PET-Adjusted IMRT for NSCLC Trial (PAINT)
Enrollment Status: Completed
Publish Date: January 25, 2024
Intervention Type: Procedure, Drug, Radiation
Study Phase: Phase 2
A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Radiation, Drug
Study Drug: Chemotherapy drug
Study Phase: Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
A Phase I Study of Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
A Phase I Study of Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
Enrollment Status: Terminated
Publish Date: November 01, 2021
Intervention Type: Radiation
Study Phase: Not Applicable
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Enrollment Status: Completed
Publish Date: May 29, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 13 Less Clinical Trials

115 Total Publications

Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small Cell Lung Cancer.
Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small Cell Lung Cancer.
Journal: Thoracic surgery clinics
Published: November 19, 2025
View All 115 Publications
Similar Doctors
Advanced in Retroperitoneal Liposarcoma
Dr. Kaled M. Alektiar
Radiation Oncology
Advanced in Retroperitoneal Liposarcoma
Dr. Kaled M. Alektiar
Radiation Oncology

Memorial Radiation Oncology Group

500 Westchester Ave, 
West Harrison, NY 
 (12.8 miles away)
914-367-7105
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist in West Harrison, New York. Dr. Alektiar is rated as an Elite provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy.

Advanced in Retroperitoneal Liposarcoma
Dr. Charles B. Simone
Radiation Oncology
Advanced in Retroperitoneal Liposarcoma
Dr. Charles B. Simone
Radiation Oncology

Memorial Radiation Oncology Group

1275 York Ave, 
New York, NY 
 (9.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Simone is a Radiation Oncologist in New York, New York. Dr. Simone is rated as a Distinguished provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Pleuropulmonary Blastoma.

Advanced in Retroperitoneal Liposarcoma
Dr. Arpit M. Chhabra
Radiation Oncology
Advanced in Retroperitoneal Liposarcoma
Dr. Arpit M. Chhabra
Radiation Oncology

The New York Proton Center

225 E 126th St, 
New York, NY 
 (6.0 miles away)
646-968-9064
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arpit Chhabra is a Radiation Oncologist in New York, New York. Dr. Chhabra is rated as an Advanced provider by MediFind in the treatment of Retroperitoneal Liposarcoma. His top areas of expertise are Pineoblastoma, Nasopharyngeal Carcinoma, Medulloblastoma, and Sinus Cancer.

VIEW MORE RETROPERITONEAL LIPOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohri's expertise for a condition
ConditionClose
  • Elite
  • Lung Cancer
    Dr. Ohri is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Distinguished
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Ohri is
    Distinguished
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Advanced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Ohri is
    Advanced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. Ohri is
    Advanced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Adrenal Cancer
    Dr. Ohri is
    Advanced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Ohri is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anal Cancer
    Dr. Ohri is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angiosarcoma of the Scalp
    Dr. Ohri is
    Advanced
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
View All 46 Advanced Conditions
  • Experienced
  • Adrenocortical Carcinoma
    Dr. Ohri is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Ohri is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. Ohri is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Angiosarcoma
    Dr. Ohri is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Astrocytoma
    Dr. Ohri is
    Experienced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Ohri is
    Experienced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
View All 52 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.